Equities Analysts Offer Predictions for MNPR Q1 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities research analysts at Brookline Capital Management issued their Q1 2025 earnings per share (EPS) estimates for shares of Monopar Therapeutics in a research report issued on Monday, January 6th. Brookline Capital Management analyst K. Dolliver forecasts that the company will post earnings of ($0.78) per share for the quarter. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. Brookline Capital Management also issued estimates for Monopar Therapeutics’ Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($1.27) EPS and FY2025 earnings at ($4.07) EPS.

Other analysts have also issued research reports about the stock. HC Wainwright raised their price target on shares of Monopar Therapeutics from $6.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Rodman & Renshaw started coverage on Monopar Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $50.00 price target for the company.

Monopar Therapeutics Price Performance

NASDAQ:MNPR opened at $24.46 on Thursday. The company has a 50 day moving average price of $21.43 and a 200-day moving average price of $10.45. Monopar Therapeutics has a 1-year low of $1.54 and a 1-year high of $38.50. The firm has a market cap of $129.10 million, a price-to-earnings ratio of -12.42 and a beta of 1.23.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09.

Insider Transactions at Monopar Therapeutics

In other news, CFO Karthik Radhakrishnan purchased 1,550 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was purchased at an average cost of $16.25 per share, for a total transaction of $25,187.50. Following the completion of the transaction, the chief financial officer now owns 1,550 shares of the company’s stock, valued at $25,187.50. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 34.90% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.